CBD and Hemp Plays Positioned for a Big Year

HENDERSON, NV / ACCESSWIRE / December 27, 2018 / After some selling at the end of the year, the cannabis sector looks prime for a major rally.Here are a few securities in the industry that look particularly well-positioned for a big 2019.

Cannabis stocks we are highlighting include: Chineseinvestors.com, Inc. (CIIX), Hemp, Inc. (OTC PINK: HEMP), CV Sciences, Inc. (CVSI), Kali, Inc. (KALY), and Cronos Group Inc. (NASDAQ: CRON).

The first on our list is US-based ChineseInvestors.com, Inc. (CIIX) (Market Cap: $19.725M, Share Price: $0.51) focuses on selling industrial hemp-based CBD products in China that could be a serious beneficiary from the farm bill.CIIX just made a major announcement of an Exclusive License for the Global Asian Market for VitaMist Products and Development of and License to Sell a New Sprayable Vitamin and Vitamin/CBD Product Line Designed Exclusively for ChineseInvestors.com, Inc. for the Global Asian Market.

CIIX, a premier provider of industrial, hemp-derived CBD products and other hemp health products for the global Chinese community, has placed initial product orders with BCDBG, Inc. for VitaMist products. The timing of this agreement for licensing and product development is critical as some industry leaders believe that a final farm bill, including provisions for the legalization of industrial hemp at a federal level is expected to reach completion this week or by the end of the year.

CIIX just appointed Alex Hamilton as Chief Financial Officer of its wholly-owned subsidiary, CBD Biotechnology, LTD.He will be overseeing a company that's recent reports show a 70% increase in revenues buoyed by an 800% increase in sales.

Hemp, Inc. (HEMP) (Market Cap: $25.637M, Share Price: $0.0340) has been on a roll following Congress's passing of the farm bill which, included in its verbiage, federally legalized mass production and farming of hemp.

CV Sciences, Inc. (CVSI) (Market Cap: $411.403M, Share Price: $4.30) will be participating as a presenter at the Biotech Showcaseâ„¢ investor and networking conference on Monday, January 7, 2019. The conference is in its eleventh year and provides companies with opportunities to network with investors, sector analysts, bankers and industry professionals.

Kali, Inc. (KALY) (Market Cap: $28.205M, Share Price: $0.0277) announced the new Kali Cannabis Therapies subsidiary to develop cannabis biotechnology treatment alternatives to chemical pharmaceuticals.On November 15th, 2018, KALY acquired NCM Biotech to include a patented cannabis extraction process and associated intellectual properties consisting of years of preclinical research studies surrounding a multitude of applications of cannabis extracts derived from the patented cannabis extraction process.

Cronos Group Inc. (CRON) (Market Cap: $1.812B, Share Price: $10.18) recently announced Altria decided to buy a 45% stake in the company for $1.8 billion.Some of the companies above such as CIIX, could be in line for similar investments.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting").Regal Consulting has agreed to a five- month term consulting agreement with the CIIX dated 8/2/18.The agreement calls for $30,000 in cash and 20,000 restricted 144 shares of CIIX per month. The Issuer CIIX has agreed to increase the monthly cash payment to $45,000 for September.Issuer has agreed to increase the monthly cash payment to $49,000 for October. Issuer has agreed to increase the monthly cash payment to $49,000 for November. All payments were made directly by ChineseInvestors.com, Inc. to provide investor relations services, of which this article is a part of.Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting has a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice.This article is based on public information and the opinions of Regal Consulting. CIIX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein.Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.